Docoh
Loading...

Thu. 18 Nov 2021, 9:15am ETBenzinga
In: Biotech, News, FDA, General

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces that Mary Crowley Cancer Research center in Dallas, Texas is now actively screening and enrolling advanced breast cancer patients in the Phase I/IIa combination study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s checkpoint inhibitors, retifanlimab and epacadostat.

Dr. Minal Barve, the Executive Medical Director and Chief Medical Officer for Mary Crowley Cancer Research center and Board-Certified in medical oncology and internal medicine, will act as the clinical site’s Principal Investigator. Dr. Barve will work closely with Cancer Insight, LLC to manage the clinical and regulatory aspects of the Phase I/IIa clinical trial in advanced breast cancer on behalf of BriaCell.

In addition to Mary Crowley Cancer Research center, the clinical sites at St. Joseph Health-Sonoma County, Santa Rosa, Calif. and the Cancer Center of Kansas, Wichita, Kan. are open and actively enrolling patients for BriaCell’s Phase I/IIa advanced breast cancer clinical trial.

“We look forward to supporting BriaCell’s efforts to develop safe and effective therapeutics for advanced breast cancer patients with few, if any, treatment options,” stated Dr. Barve.

“We are delighted to add Mary Crowley Cancer Research center with Dr. Barve as Principal Investigators to our team. Dr. Barve’s leading knowledge and experience in biological therapies and immunotherapies for cancer will be highly valuable to us. We look forward to working with her team in our advanced breast cancer clinical trial to accelerate patient recruitment,” stated Dr. Williams, BriaCell’s President and CEO.

BriaCell anticipates the addition of the Mary Crowley Cancer Research center clinical sites may accelerate patient enrolment to build on our existing patient data. BriaCell had previously reported 12.0 months average overall survival in advanced breast cancer patients in its Phase I/IIa combination study including 13.4 months in patients with 2+ HLA matches and 12.5 months in patients with Grade I/II tumors, compared with 7.2-9.8 months survival in historical comparison treatment studies. The top responder patient showed 21.4 months survival plus 100% resolution of ‘eye-bulging’ orbital tumor.

Founded by Dallas entrepreneur Mary C. Crowley and her fundamental belief that cancer patients needed access to better cancer treatments, Mary Crowley Cancer Research center was established in 1997 to provide potentially curative treatments for adult cancer patients. Mary Crowley Cancer Research center’s mission is to bring hope to cancer patients through innovative clinical trials, while advancing treatment for patients in the future.